VEGF Trap-Eye: New Treatment for wet Age-Related Macular Degeneration (AMD)

News VEGF Trap-Eye

New Drug Is Effective Against Potentially Blinding Retinal Diseases

VEGF Trap-Eye Clinical Trial Results Will Be Presented at the American Academy of Ophthalmology 2011 Annual Meeting

The comprehensive year-one findings of the VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) 1 and 2 studies will be reported by Ursula Schmidt-Erfurth, MD, of the Medical University of Vienna, Austria. Results of the Controlled Phase 3 Evaluation of Repeated intravitreal administration of VEGF Trap-Eye in Central retinal vein occlusion: Utility and Safety (COPERNICUS) study will be reported by Julia Haller, MD, of the Wills Eye Institute in Philadelphia.

April 18, 2011 FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration

FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). The FDA also granted the Company's request for priority review of its BLA. A Priority Review designation is given to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. Under priority review, the target date for an FDA decision on the VEGF Trap-Eye BLA is August 20, 2011.

inpharm.com: Bayer drug enters phase III for diabetic macular oedema

Bayer drug enters phase III for diabetic macular oedema

Bayer and Regeneron hope their drug will be a major challenger to Lucentis

The Angiogenesis Foundation: Antiangiogenic Eye Drug Shows Positive Results For Treating Leading Cause of Vision Loss in the Elderly in Two Late-stage Clinical Trials

Antiangiogenic Eye Drug Shows Positive Results For Treating Leading Cause of Vision Loss

A new experimental antiangiogenic drug, called VEGF Trap-Eye (aflibercept ophthalmic solution) is being tested for its ability to being benefits over these current therapies. VEGF Trap-Eye is a protein that binds to and inactivates a growth factor called VEGF (vascular endothelial growth factor) that stimulate blood vessel growth in AMD.

OSNSuperSite: Anti-VEGF therapy finds expanding role in ophthalmology

Anti-VEGF therapy finds expanding role in ophthalmology

Anti-VEGF therapy, introduced to ophthalmology less than a decade ago, has fast become a mainstay of managing diseases such as age-related macular degeneration and may expand to even more indications.

BAYNEWS: Wet age-related macular degeneration

Wet age-related macular degeneration:

The clinical Phase III development program for VEGF Trap-Eye conducted by Bayer Schering Pharma and Regeneron Pharmaceuticals in wet age-related macular degeneration (wet AMD) is progressing extremely well. The 52-week results from the two major VIEW 1 and VIEW 2 studies are expected before the end of the year.

Zur Übersicht EYLEA (VEGF Trap-Eye) bei feuchter Makuladegeneration